Skip to main content
Top
Published in: Journal of Neural Transmission 3/2013

Open Access 01-03-2013 | Movement Disorders - Review article

Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy

Authors: Wolfgang H. Jost, Harald Hefter, Andrea Stenner, Gerhard Reichel

Published in: Journal of Neural Transmission | Issue 3/2013

Login to get access

Abstract

Botulinum neurotoxin is the therapy of choice for all forms of cervical dystonia (CD), but treatment regimens still vary considerably. The interpretation of treatment outcome is mainly based on the clinical experience and on the scientific value of the rating scales applied. The aim of this review is to describe the historical development of rating scales for the assessment of CD and to provide an appraisal of their advantages and drawbacks. The Tsui score and the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) have been widely employed in numerous clinical studies as specific instruments for CD. The obvious advantage of the Tsui score is its simplicity so that it can be easily implemented in clinical routine. The TWSTRS allows a more sophisticated assessment of functional features of CD, but only the Tsui score includes a rating for tremor. Other benefits of the TWSTRS are the disability and pain subscales, but despite its value in clinical trials, it might be too complex for routine clinical practice. None of the rating scales used at present has been rigorously tested for responsiveness to detect significant changes in clinical status after therapeutic interventions. Moreover, clinical data support a new classification of CD leading to a differentiation between head and neck subtypes. As the current rating scales are not able to cover all these aspects of the disorder, further research is needed to develop a valid and reliable instrument which considers the most current classification of CD.
Literature
go back to reference Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951PubMedCrossRef Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951PubMedCrossRef
go back to reference Blackie JD, Lees AJ (1990) Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 53(8):640–643PubMedCrossRef Blackie JD, Lees AJ (1990) Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 53(8):640–643PubMedCrossRef
go back to reference Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46(4):1066–1072PubMedCrossRef Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, van Hilten JJ, van der Kamp W, Prins MH, Speelman JD (1996) Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46(4):1066–1072PubMedCrossRef
go back to reference Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53(7):1439–1446PubMedCrossRef Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53(7):1439–1446PubMedCrossRef
go back to reference Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O’Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53(7):1431–1438PubMedCrossRef Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O’Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53(7):1431–1438PubMedCrossRef
go back to reference Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35(1):73–77PubMedCrossRef Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 35(1):73–77PubMedCrossRef
go back to reference Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, Hobart JC (2004a) Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology 63(9):1629–1633PubMedCrossRef Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, Hobart JC (2004a) Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology 63(9):1629–1633PubMedCrossRef
go back to reference Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2004b) Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord 19(9):1054–1059PubMedCrossRef Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2004b) Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord 19(9):1054–1059PubMedCrossRef
go back to reference Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2006) CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 67(12):2230–2232PubMedCrossRef Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT (2006) CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 67(12):2230–2232PubMedCrossRef
go back to reference Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia—clinical characteristics. Mov Disord 6:119–126PubMedCrossRef Chan J, Brin MF, Fahn S (1991) Idiopathic cervical dystonia—clinical characteristics. Mov Disord 6:119–126PubMedCrossRef
go back to reference Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG (1992) Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42(4):878–882PubMedCrossRef Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG (1992) Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42(4):878–882PubMedCrossRef
go back to reference Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE (1997) Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 12(4):570–575PubMedCrossRef Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE (1997) Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 12(4):570–575PubMedCrossRef
go back to reference Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, Dystonia Study Group (2003) Rating scales for dystonia: a multicenter assessment. Mov Disord 18(3):303–312PubMedCrossRef Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, Dystonia Study Group (2003) Rating scales for dystonia: a multicenter assessment. Mov Disord 18(3):303–312PubMedCrossRef
go back to reference Consky ES, Lang AE (1994) Clinical assessments of patients with cervical dystonia. In: Jancovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 211–237 Consky ES, Lang AE (1994) Clinical assessments of patients with cervical dystonia. In: Jancovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 211–237
go back to reference Consky ES, Basinki A, Belle L, Ranawaya R, Lang AE (1990) The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 40(suppl 1):445 Consky ES, Basinki A, Belle L, Ranawaya R, Lang AE (1990) The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 40(suppl 1):445
go back to reference Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005a) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 25(1):CD003633 Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005a) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 25(1):CD003633
go back to reference Costa J, Borges A, Espírito-Santo C, Ferreira J, Coelho M, Moore P, Sampaio C (2005b) Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 25(1):CD004314 Costa J, Borges A, Espírito-Santo C, Ferreira J, Coelho M, Moore P, Sampaio C (2005b) Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 25(1):CD004314
go back to reference Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005c) Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 25(1):CD004315 Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005c) Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 25(1):CD004315
go back to reference Dubinsky RM, Gray CS, Vetere-Overfield B, Koller WC (1991) Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 14(3):262–267PubMedCrossRef Dubinsky RM, Gray CS, Vetere-Overfield B, Koller WC (1991) Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol 14(3):262–267PubMedCrossRef
go back to reference Fahn S (1989) Assessment of primary dystonias. In: Munsat TL (ed) Quantification of neurologic deficit. Butterworths, London, pp 241–270 Fahn S (1989) Assessment of primary dystonias. In: Munsat TL (ed) Quantification of neurologic deficit. Butterworths, London, pp 241–270
go back to reference Gelb DJ, Lowenstein DH, Aminoff MJ (1989) Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39(1):80–84PubMedCrossRef Gelb DJ, Lowenstein DH, Aminoff MJ (1989) Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39(1):80–84PubMedCrossRef
go back to reference Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40(8):1213–1218PubMedCrossRef Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E (1990) Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40(8):1213–1218PubMedCrossRef
go back to reference Jankovic J, Tolosa E (2007) Parkinsons’s disease and movement disorders, 5th edn. Lippincott Williams & Wilkins, Philadelphia Jankovic J, Tolosa E (2007) Parkinsons’s disease and movement disorders, 5th edn. Lippincott Williams & Wilkins, Philadelphia
go back to reference Kamm C, Benecke R (2011) Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies. Clin Invest 1(6):891–900CrossRef Kamm C, Benecke R (2011) Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies. Clin Invest 1(6):891–900CrossRef
go back to reference Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD (1997) Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49(3):701–707PubMedCrossRef Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, Brin MF, Jankovic J, Rodnitzky RL, Singer C, Swenson MR, Tarsy D, Murray JJ, Koller M, Wallace JD (1997) Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49(3):701–707PubMedCrossRef
go back to reference Lindeboom R, Brans JW, Aramideh M, Speelman HD, De Haan RJ (1998) Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord 13(4):706–712PubMedCrossRef Lindeboom R, Brans JW, Aramideh M, Speelman HD, De Haan RJ (1998) Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord 13(4):706–712PubMedCrossRef
go back to reference Moore AP, Blumhardt LD (1991) A double blind trial of botulinum toxin “A” in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry 54(9):813–816PubMedCrossRef Moore AP, Blumhardt LD (1991) A double blind trial of botulinum toxin “A” in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry 54(9):813–816PubMedCrossRef
go back to reference Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W (2004) Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 75(5):749–753PubMedCrossRef Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W (2004) Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 75(5):749–753PubMedCrossRef
go back to reference O’Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O’Neil T, Factor S, Seeberger L (2001) Cervical dystonia severity scale reliability study. Mov Disord 16(6):1086–1090PubMedCrossRef O’Brien C, Brashear A, Cullis P, Truong D, Molho E, Jenkins S, Wojcieszek J, O’Neil T, Factor S, Seeberger L (2001) Cervical dystonia severity scale reliability study. Mov Disord 16(6):1086–1090PubMedCrossRef
go back to reference Odergren T, Tollbäck A, Borg J (1994) Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Scand J Rehabil Med 26(4):191–195PubMed Odergren T, Tollbäck A, Borg J (1994) Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Scand J Rehabil Med 26(4):191–195PubMed
go back to reference Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23(4):510–517PubMedCrossRef Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 23(4):510–517PubMedCrossRef
go back to reference Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G, German Dystonia Study Group (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64(1):13–17PubMedCrossRef Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Künig G, German Dystonia Study Group (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64(1):13–17PubMedCrossRef
go back to reference Reichel G (2011) Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. Basal Ganglia 1:5–12CrossRef Reichel G (2011) Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. Basal Ganglia 1:5–12CrossRef
go back to reference Scientific Advisory Group of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11(3):193–205CrossRef Scientific Advisory Group of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11(3):193–205CrossRef
go back to reference Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallet M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706PubMedCrossRef Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallet M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706PubMedCrossRef
go back to reference Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22(2):95–100PubMed Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 22(2):95–100PubMed
go back to reference Sommer S, Viga R, Petersen H, Koletzki E, Jost W (2009) Zerviton: a new tool to measure head position in patients with cervical dystonia: preliminary results. Mov Disord 24(Suppl 1):117–118 Sommer S, Viga R, Petersen H, Koletzki E, Jost W (2009) Zerviton: a new tool to measure head position in patients with cervical dystonia: preliminary results. Mov Disord 24(Suppl 1):117–118
go back to reference Stell R, Thompson PD, Marsden CD (1988) Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 51(7):920–923PubMedCrossRef Stell R, Thompson PD, Marsden CD (1988) Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 51(7):920–923PubMedCrossRef
go back to reference Tarsy D (1997) Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 12(1):100–102PubMedCrossRef Tarsy D (1997) Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 12(1):100–102PubMedCrossRef
go back to reference Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20(7):783–791PubMedCrossRef Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20(7):783–791PubMedCrossRef
go back to reference Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB (1985) A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12(4):314–316PubMed Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB (1985) A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12(4):314–316PubMed
go back to reference Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2(8501):245–247PubMedCrossRef Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2(8501):245–247PubMedCrossRef
go back to reference Tsui JK, Fross RD, Calne S, Calne DB (1987) Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 14(3 Suppl):533–555PubMed Tsui JK, Fross RD, Calne S, Calne DB (1987) Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci 14(3 Suppl):533–555PubMed
go back to reference Weiner WJ, Lang AE (1989) Movement disorders: a comprehensive survey. Futura, Mount Kisco, NY Weiner WJ, Lang AE (1989) Movement disorders: a comprehensive survey. Futura, Mount Kisco, NY
Metadata
Title
Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy
Authors
Wolfgang H. Jost
Harald Hefter
Andrea Stenner
Gerhard Reichel
Publication date
01-03-2013
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 3/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-012-0887-7

Other articles of this Issue 3/2013

Journal of Neural Transmission 3/2013 Go to the issue

Neurology and Preclinical Neurological Studies - Original Article

Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy

Neurology and Preclinical Neurological Studies - Original Article

Levodopa changes brain motor network function during ankle movements in Parkinson’s disease